Profile

Hetero is a globally renowned vertically integrated pharmaceutical player engaged in research and development, manufacturing, and marketing of high-quality chemical and biologic medicines across diverse therapeutic areas. Backed by 27+ years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, Global Generics, Biosimilars and Custom Pharmaceutical Services. The company is among the largest producers of Active Pharmaceutical Ingredients (APIs) in the world.

Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, which has been approved by top pharma regulatory bodies of the world. Our portfolio includes 300+ products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology etc. Hetero has a strong global presence in over 126 countries and focusses on making affordable medicines accessible to patients worldwide.

Over the years, Hetero has established its strong leadership in ARVs and Antiviral therapies and caters to 40% of existing global demand for Anti-Retroviral (ARV) APIs and Finished Dosage Forms (FDFs) used in HIV/AIDS treatment.

A track record of responding to Global Public Health Emergencies

The highlight of Hetero’s 27+ years of existence has been its responsive actions to mitigate pandemics and life-threatening diseases afflicting communities across the world. By partnering with innovators for developing Oseltamivir to fight against Swine Flu Pandemic to enabling access to affordable Hepatitis C medicines in underdeveloped countries, Hetero has always endeavoured to do its bit at times of global health crises and save precious lives.

Since the onset of the Covid-19 pandemic, Hetero has been proactive in responding to the various challenges surrounding it. It has been the first company to launch the licensed version of generic Remdesivir under the brand name ‘Covifor’ in India for treating severely infected patients and followed it up with Favipiravir (Favivir) to provide succor to those affected by mild and moderate symptoms. As of today, the company is among the largest manufacturers of Remdesivir globally.

Illustrating its continuing commitment to play its part in the global fight against the pandemic, Hetero has entered into an agreement with the Russian Direct Investment Fund (RDIF) as a manufacturing partner for producing 100 million doses of the Sputnik V vaccine per year. This development also showcases Hetero’s enduring spirit of collaboration and penchant for contributing to global health and well-being.